arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Atara Biotherapeutics, Inc.

ATRA
$8.55 ▼ -0.38 (-4.26%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
54 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
44
Health
Weak
Moderately Bullish
auto_awesome

Analytical Summary

Atara Biotherapeutics, Inc. demonstrates solid fundamentals with strength in Profit Margin (%). However, watch Return on Common Equity (%) which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $128.5M
Dividend Yield
Revenue Growth -96.4%
Op. Margin None
ROIC 12.8%
FCF / Share $-0.22
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

54-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$630.00K
↓ -96.4%
Net Income Profit after all expenses
$-4.14M
— 0.0%
Operating Margin Operating profit as % of sales
-160.7%
↓ -55.2% 86th
FCF / Share Free cash flow per share
$-0.22
↓ -1.7%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
60
Returns
11
Financial Health
82
Cash Quality
8

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 14 years · 54 quarters